Liquidia (NASDAQ:LQDA) Price Target Raised to $55.00 at HC Wainwright

Liquidia (NASDAQ:LQDA) had its price target raised by HC Wainwright from $50.00 to $55.00 in a research note issued to investors on Friday,Benzinga reports. The brokerage currently has a buy rating on the stock. HC Wainwright also issued estimates for Liquidia’s Q4 2025 earnings at $0.33 EPS, FY2025 earnings at ($0.64) EPS, Q1 2026 earnings at $0.43 EPS, Q1 2026 earnings at $0.35 EPS, Q2 2026 earnings at $0.49 EPS, Q2 2026 earnings at $0.62 EPS, Q3 2026 earnings at $0.86 EPS, Q4 2026 earnings at $0.98 EPS, Q4 2026 earnings at $0.86 EPS, FY2026 earnings at $2.89 EPS, FY2027 earnings at $2.97 EPS, FY2028 earnings at $4.97 EPS, FY2029 earnings at $7.57 EPS and FY2030 earnings at $9.85 EPS.

Several other research analysts also recently weighed in on LQDA. BTIG Research restated a “buy” rating and issued a $49.00 price target on shares of Liquidia in a research note on Friday, January 9th. Raymond James Financial restated a “strong-buy” rating on shares of Liquidia in a research report on Thursday. Wall Street Zen downgraded shares of Liquidia from a “buy” rating to a “hold” rating in a report on Sunday, January 18th. Needham & Company LLC reissued a “buy” rating and set a $52.00 price objective on shares of Liquidia in a report on Wednesday, February 25th. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Liquidia in a research report on Thursday, January 22nd. Two equities research analysts have rated the stock with a Strong Buy rating, seven have assigned a Buy rating, one has assigned a Hold rating and two have given a Sell rating to the stock. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average price target of $42.00.

Liquidia Price Performance

NASDAQ:LQDA traded up $1.51 on Friday, reaching $36.03. 2,306,542 shares of the company’s stock traded hands, compared to its average volume of 1,900,515. The stock has a 50-day simple moving average of $37.10 and a 200-day simple moving average of $30.89. Liquidia has a 12 month low of $11.26 and a 12 month high of $46.67. The firm has a market cap of $3.13 billion, a PE ratio of -43.41, a P/E/G ratio of 0.60 and a beta of 0.52. The company has a quick ratio of 1.96, a current ratio of 2.20 and a debt-to-equity ratio of 6.19.

Liquidia (NASDAQ:LQDA) last released its quarterly earnings data on Thursday, March 5th. The company reported $0.15 earnings per share for the quarter, missing analysts’ consensus estimates of $0.33 by ($0.18). The business had revenue of $92.02 million during the quarter. Liquidia had a negative return on equity of 237.79% and a negative net margin of 43.53%.Liquidia’s revenue for the quarter was up 3072.4% on a year-over-year basis. Equities research analysts forecast that Liquidia will post -1.51 earnings per share for the current year.

Insider Buying and Selling at Liquidia

In other Liquidia news, CEO Roger Jeffs sold 66,610 shares of Liquidia stock in a transaction on Monday, January 12th. The shares were sold at an average price of $37.43, for a total value of $2,493,212.30. Following the completion of the transaction, the chief executive officer directly owned 1,037,528 shares of the company’s stock, valued at $38,834,673.04. This trade represents a 6.03% decrease in their position. The sale was disclosed in a filing with the SEC, which is available at this link. Also, CFO Michael Kaseta sold 36,932 shares of the company’s stock in a transaction dated Monday, January 12th. The shares were sold at an average price of $37.43, for a total transaction of $1,382,364.76. Following the sale, the chief financial officer owned 350,919 shares in the company, valued at $13,134,898.17. This represents a 9.52% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders have sold 212,534 shares of company stock valued at $7,964,719 over the last ninety days. Corporate insiders own 26.50% of the company’s stock.

Institutional Investors Weigh In On Liquidia

Institutional investors have recently modified their holdings of the stock. Seven Fleet Capital Management LP purchased a new position in shares of Liquidia in the 4th quarter worth approximately $3,148,000. Invesco Ltd. raised its holdings in Liquidia by 428.3% during the 4th quarter. Invesco Ltd. now owns 420,621 shares of the company’s stock valued at $14,507,000 after buying an additional 341,009 shares during the period. XTX Topco Ltd bought a new stake in Liquidia in the fourth quarter worth $1,214,000. nVerses Capital LLC purchased a new position in Liquidia during the fourth quarter worth $335,000. Finally, Occudo Quantitative Strategies LP bought a new position in Liquidia during the fourth quarter valued at $3,107,000. 64.54% of the stock is owned by institutional investors.

More Liquidia News

Here are the key news stories impacting Liquidia this week:

• Positive Sentiment: Commercial momentum and profitability — Liquidia reported YUTREPIA net product sales of $90.1M in Q4 and $148.3M for 2025, achieved a second consecutive profitable quarter (Q4 net income $14.6M) and positive adjusted EBITDA, signaling rapid launch adoption and improving unit economics. GlobeNewswire Release
• Positive Sentiment: Balance sheet strength — the company ended 2025 with ~$190.7M in cash, improving liquidity and backing management’s plan to fund commercial expansion and clinical programs from operations. Quiver Quant Summary
• Positive Sentiment: Analyst upgrades and higher price targets — several firms raised ratings/targets after the quarter (HC Wainwright to $55, Needham to $54, BTIG to $50, Wells Fargo to $44), which supports further upside and likely contributed to intraday buying. Benzinga Analyst Roundup
• Neutral Sentiment: Mixed EPS headlines — Liquidia reported GAAP EPS of $0.15 for Q4. That missed some sell‑side consensus figures (~$0.33) but beat other estimates (Zacks cited $0.08), creating mixed investor interpretation of the results. Zacks Coverage
• Neutral Sentiment: Earnings materials and management commentary available — the slide deck and transcript provide color on commercial adoption, prescriber metrics and plans to fund L606 and other programs; useful for assessing sustainability of the launch. Earnings Presentation (Seeking Alpha)
• Negative Sentiment: Initial market reaction to the EPS headline — shares gapped down on the earnings headline before rebounding, showing sensitivity to EPS versus revenue/profitability nuance. That initial gap indicates headline risk if future quarters miss expectations. DefenseWorld: Gap Down
• Negative Sentiment: Insider and institutional sales — recent filings and summaries show notable insider sell activity and some large institutional reductions, which can weigh on sentiment if sustained. Fool: SEC Filing

Liquidia Company Profile

Liquidia Technologies, Inc is a clinical-stage biopharmaceutical company headquartered in Research Triangle Park, North Carolina. The company leverages its proprietary PRINT® (Particle Replication In Non-wetting Templates) platform to engineer precisely shaped and sized drug particles, with the goal of improving delivery, efficacy and safety profiles. By controlling particle characteristics at the nanoscale, Liquidia seeks to enhance respiratory and other therapies that depend on targeted delivery.

The company’s lead product candidate, LIQ861, is a dry powder formulation of treprostinil designed for inhalation in patients with pulmonary arterial hypertension (PAH).